Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The gradual loss of DNA from the ends of telomeres has been implicated in the control of cellular proliferative potential. Telomerase is an enzyme that restores telomeric DNA sequences, and expression of its activity was thought to be essential for the immortalization of human cells, both in vitro and in tumor progression in vivo. Telomerase activity has been detected in 50-100% of tumors of different types, but not in most normal adult somatic tissues. It has also been detected in about 70% of human cell lines immortalized in vitro and in all tumor-derived cell lines examined to date. It has previously been shown that in vitro immortalized telomerase-negative cell lines acquire very long and heterogeneous telomeres in association with immortalization presumably via one or more novel telomere-lengthening mechanisms that we refer to as ALT (alternative lengthening of telomeres). Here we report evidence for the presence of ALT in a subset of tumor-derived cell lines and tumors. The maintenance of telomeres by a mechanism other than telomerase, even in a minority of cancers, has major implications for therapeutic uses of telomerase inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a few rare tumors (29) and some experimentally immortalized cell lines (30) lack detectable telomerase activity.”
From Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death (1999) · cites this paper as [30]
In the citing paper
“Virally transformed human cells that eliminate p53 and/or pRB function can escape crisis at very low frequencies, and invariably adopt telomere-maintenance programs: 80-90% of human tumors possess some telomerase activity, while the remainder maintain telomeres via a recombination-mediated process termed ALT (for Alternative Lengthening of Telomeres)37-40.”
From Telomere dysfunction and tumour suppression: the senescence connection (2008) · cites this paper as [39]
In the citing paper
“A significant number of human tumours can also maintain telomeres by recombination-based ALT mechanisms in the absence of telomerase 72 .”
From The common biology of cancer and ageing (2007) · cites this paper as [72]
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Telomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Identification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400
Counter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., & Bacchetti, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05245.x · Cited by 2,096
Telomere reduction in human colorectal carcinoma and with ageing
Hastie, N. D., Dempster, M., Dunlop, M. G., Thompson, A. M., Green, D. K., & Allshire, R. C. (1990) · Nature · doi:10.1038/346866a0 · Cited by 1,650
Telomere elongation in immortal human cells without detectable telomerase activity
Bryan, T. M., Englezou, A., Gupta, J., Bacchetti, S., & Reddel, R. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00098.x · Cited by 1,279
Self-citationTelomere loss: mitotic clock or genetic time bomb?
Harley, C. B. (1991) · Mutation Research/DNAging · doi:10.1016/0921-8734(91)90018-7 · Cited by 1,139
An alternative pathway for yeast telomere maintenance rescues est1− senescence
Lundblad, V., & Blackburn, E. H. (1993) · Cell · doi:10.1016/0092-8674(93)90234-h · Cited by 942
Telomerase activity in human ovarian carcinoma.
Counter, C. M., Hirte, H. W., Bacchetti, S., & Harley, C. B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.2900 · Cited by 677
Cited by
Items 901–1,000 of 1,000
Telomerase: is it the future diagnostic and prognostic tool in human cancer?
Mabruk, M. J. E. M. F., & O’Flatharta, C. (2005) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.5.6.907 · Cited by 13
Immunohistochemical telomeric-repeat binding factor-1 expression in gastrointestinal tumors.
Aragona, M., Buda, C. A., Panetta, S., Morelli, M., Giudice, A. L., Campagna, F., Pontoriero, A., Cascinu, S., & Torre, F. L. (2000) · Oncology Reports · doi:10.3892/or.7.5.987 · Cited by 11
Extrachromosomal RNA–DNA complex containing long telomeric repeats in chironomids
Rosén, M., Kamnert, I., & Edström, J. (2002) · Insect Molecular Biology · doi:10.1046/j.1365-2583.2002.00322.x · Cited by 11
“Mammalian cells are also sometimes capable of telomeraseindependent telomere maintenance (Bryan et al. , 1995, 1997), known as alternative lengthening of telomeres (ALT), which involves recombination between telomeres Received 13 September 2001; accepted after revision 3 December 2001.”
BackgroundC. eleganssurvivors without telomerase
Lackner, D. H., & Karlseder, J. (2012) · Worm · doi:10.4161/worm.21073 · Cited by 10
Biomolecular Condensates in Telomere Maintenance of ALT Cancer Cells
Yu, X., & Zhang, H. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.168951 · Cited by 10
[Telomerase and telomere: their structure and dynamics in health and disease].
Gómez, D. L. M., Armando, R. G., Fariña, H. G., & Gomez, D. E. (2014) · PubMed · Cited by 11
Telomere function in colorectal cancer
Frías, C., Morán, A., de Juan, C., Ortega, P., Fernández‐Marcelo, T., Sánchez-Pernaute, A., Torres, A. J., Díaz-Rubio, E., Benito, M., & Iniesta, P. (2009) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v1.i1.3 · Cited by 10
Genetic Predisposition to Myelodysplastic Syndromes: A Challenge for Adult Hematologists
Crisà, E., Boggione, P., Nicolosi, M., Mahmoud, A. M., Essa, W. A., Awikeh, B., Aspesi, A., Andorno, A., Boldorini, R. L., Dianzani, I., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052525 · Cited by 9
“In each cell division, a physiological loss of a certain number of telomeric sequences is unavoidable; however, two biological systems reduce the DNA loss at the chromosome ends: (i) alternative lengthening of telomeres, by which DNA sequences are copied from one telomere to another [55,56]; (ii) telomerase complex, t…”
BackgroundTelomeres cooperate with the nuclear envelope to maintain genome stability
Rai, R., Sodeinde, T., Boston, A. M., & Chang, S. S. (2023) · BioEssays · doi:10.1002/bies.202300184 · Cited by 9
“87] ALT utilizes RAD51 or RAD52 mediated-HDR pathway to elongate telomeres in 10%–15% of human cancers.”
BackgroundSuper-telomeres in transformed human fibroblasts
Chiodi, I., Belgiovine, C., Zongaro, S., Ricotti, R., Horard, B., Lossani, A., Focher, F., Gilson, É., Giulotto, E., & Mondello, C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.03.030 · Cited by 10
“The necessity of preserving functional telomeres in tumor cells is confirmed by the observation that tumor cells lacking telomerase activity maintain telomeres through a recombination based mechanism known as alternative lengthening of telomeres (ALT) [16].”
BackgroundTelomerase is Frequently Activated in Tumors with Microsatellite Instability
de Cáceres, I. I., Frolova, N., Varkonyi, R. J., Dulaimi, E., Meropol, N. J., Broccoli, D., & Cairns, P. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.3.695 · Cited by 12
Inhibition of telomerase activity by NME2: impact on metastasis suppression?
Kar, A., & Chowdhury, S. (2014) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-014-1077-y · Cited by 9
“On the other the hand, in some tumor cell lines, a recombinationbased mechanism was found to maintain and elongate telomeres in the absence of telomerase—this was termed as alternative lengthening of telomeres (ALT) (Bryan et al., 1997).”
BackgroundRules for Making Human Tumor Cells
(2003) · New England Journal of Medicine · doi:10.1056/nejm200302133480727 · Cited by 9
van Mourik, P. M., de Jong, J., Sharma, S., Kavšek, A., Chabes, A., & Chang, M. (2018) · G3 Genes Genomes Genetics · doi:10.1534/g3.118.200280 · Cited by 12
Krapivin, M. I., Tikhonov, A. V., Efimova, O. A., Pendina, A. A., Smirnova, A. A., Chiryaeva, O. G., Евгеньевна, Т. О., Petrova, L., Dudkina, V. S., & Баранов, В. С. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126622 · Cited by 10
Birrento, M. L., Bryan, T. M., Samosorn, S., & Beck, J. L. (2015) · Journal of the American Society for Mass Spectrometry · doi:10.1007/s13361-015-1121-2 · Cited by 9
“In cancer cells, telomere length is maintained, either by the enzyme telomerase (~85-90% of cancers), or by another mechanism called Alternative Lengthening of Telomeres (ALT, ~1015% of cancers) [7].”
BackgroundSelf-citationRen, B. X., Yang, F., Zhu, G. H., Huang, Z., Ai, H., Xia, R., Liu, X. J., Lu, M., & Song, B. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02316.x · Cited by 10
Therapeutic Targets in Telomerase and Telomere Biology of Cancers
Prasad, R., Pal, D., & Mohammad, W. (2020) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-020-00876-8 · Cited by 12
Xu, J., & McEachern, M. J. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00430-12 · Cited by 9
“These structures include strand invasion between sister chromatids (1) and between nonsister chromatids (2); intratelomeric strand invasion to form a t-loop (3); subtelomeric strand invasion (4); strand invasion of a telomere end into a t-circle and rolling-circle copying (5); single- and double-stranded free t-circle…”
BackgroundKido, A., Schneider‐Stock, R., Hauptmann, K., & Roessner, A. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00189-7 · Cited by 9
Telomerase activity in canine osteosarcoma
Kow, K. Y., Bailey, S. M., Williams, E. S., Withrow, S. J., & Lana, S. E. (2006) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2006.00106.x · Cited by 9
Wu, Y., Cai, Z., Cross, D., Noble, J. R., Prest, K., Littleboy, J. B., Cohen, S. B., Edlundh, B., Koh, J. M. S., Xu, R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67190-w · Cited by 9
“A much smaller number of cancers maintain their telomeres by an Alternative Lengthening of Telomeres (ALT) mechanism that involves homologous recombination-dependent synthesis of DNA using telo-mericDNA as atemplate 4,5 .”
Self-citationTichy, E. D., Lee, J., Li, G., Estep, K. N., Johnson, F. B., & Mourkioti, F. (2023) · npj Microgravity · doi:10.1038/s41526-023-00303-1 · Cited by 8
“ALT was originally discovered in immortalized cell lines and subsequently shown to occur in some human tumors 64,65 While evidence is mounting that ALT can be regulated by environmental and genetic factors in rapidly proliferating tumor cells 44 , its modulation and engagement in quiescent…”
Targeting FANCM by antisense oligonucleotides in ALT-positive cancers
Tieo, G., Lim, N. J. X., Lim, K. W., Dröge, P., Phan, A. T., & Jeitany, M. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102492 · Cited by 10
Modeling human endothelial cell transformation in vascular neoplasias
Wen, V. W., & MacKenzie, K. L. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.012674 · Cited by 8
“…this possibility remains to be confirmed by demonstration of the specific molecular characteristics of ALTimmortalized cells, such as very long heterogeneous telomere lengths, DNA c-circles and PML bodies in angiosarcoma tissue (Bryan et al., 1997; Henson et al., 2005; Fasching et al., 2007).”
BackgroundALT cancer cells are specifically sensitive to lysine acetyl transferase inhibition
Bakhos-Douaihy, D., Desmaze, C., Jeitany, M., Gauthier, L., Biard, D. S. F., Junier, M., Chneiweiss, H., & Boussin, F. D. (2019) · Oncotarget · doi:10.18632/oncotarget.26616 · Cited by 9
“ALT is based on homologous recombination for the addition of telomere repeats [3].”
BackgroundRea, M. A., & Rice, R. H. (2001) · International Journal of Cancer · doi:10.1002/ijc.1521 · Cited by 9
Immunohistochemical Detection of hTERT Protein in Soft Tissue Sarcomas: Correlation With Tumor Grade
Sabah, M., Cummins, R., Leader, M., & Kay, E. W. (2006) · Applied immunohistochemistry & molecular morphology · doi:10.1097/01.pai.0000156606.04726.d3 · Cited by 8
“This may reflect differences in biologic characteristics between sarcomas and carcinomas, including the existence of an alternative telomerase-independent mechanism for cell immortality via telomere lengthening.(25,37,38) IHC studies on hTERT expression are sparse, and comparison with other studies using different met…”
ResultNelson, C. B., Al-Turki, T. M., Luxton, J. J., Taylor, L. E., Maranon, D. G., Muraki, K., Murnane, J. P., & Bailey, S. M. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.644803 · Cited by 8
Telomeres and telomerase in ageing and cancer
Cowell, J. K. (1999) · AGE · doi:10.1007/s11357-999-0007-2 · Cited by 8
“cell lines, albeit relatively few, and some tumors, maintain large telomeres without telomerase activity (29).”
BackgroundThree molecular determinants of malignant conversion and their potential as therapeutic targets
Dome, J. S., & Look, A. T. (1999) · Current Opinion in Oncology · doi:10.1097/00001622-199901000-00013 · Cited by 9
Telomere clustering drives ALT
Min, J., & Shay, J. W. (2019) · Aging · doi:10.18632/aging.102369 · Cited by 8
Loss of TRF2 by radiation-induced apoptosis in HL60 cells.
Nakagami, Y., Ito, M., Hara, T., & Inoue, T. (2002) · PubMed · Cited by 7
Yuan, P., Wang, Z., Lv, W., Pan, H., Yang, Y., Yuan, X., & Hu, J. (2014) · Oncology Letters · doi:10.3892/ol.2014.2306 · Cited by 7
“The ALT mechanism exists in NSCLC and thus, leads to aggressive malignant properties and the acquisition of resistant mechanisms to counteract telomerase deficiency in late generations of tumor cells (25,29).”
Practical Molecular Pathologic Diagnosis of Infiltrating Gliomas
Pekmezci, M., & Perry, A. (2014) · Surgical pathology clinics · doi:10.1016/j.path.2014.10.004 · Cited by 8
Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomas
Matsuo, T., Sugita, T., Shimose, S., Kubo, T., Ishikawa, M., Yasunaga, Y., & Ochi, M. (2008) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-27-73 · Cited by 9
“Some immortalized telomerase-negative cell lines possess extremely long and heterogeneous telomeres as an ALT, and a substantial proportion of types of sarcomas have been reported to have ALT without telomerase activity [36,37].”
BackgroundKjeldsen, E. (2017) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2017.06.002 · Cited by 7
Breast Tissue Biology Expands the Possibilities for Prevention of Age-Related Breast Cancers
Fresques, T., Zirbes, A., Shalabi, S., Samson, S., Preto, S., Stampfer, M. R., & LaBarge, M. A. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00174 · Cited by 7
“While some cancers use a homology recombination-based mechanism, termed alternative lengthening of telomeres (ALT), to become immortal, this mechanism is rarely observed in breast and most other human carcinomas (Bryan et al., 1997; Shay and Bacchetti, 1997; Subhawong et al., 2009).”
BackgroundZencir, S., Hsieh, M., Hsu, J.-S., Ergün, Y., Chou, G.-L., Li, T., Teng, S., & Topcu, Z. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03213-x · Cited by 7
Telomere Maintenance Associated Mutations in the Genetic Landscape of Gynecological Mucosal Melanoma
Yuan, G., Song, J., Li, N., Song, Q., Li, Y., Du, Y., Wang, X., Jiao, Y., & Wu, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01707 · Cited by 7
“Telomere maintenance mechanisms (TMMs) include telomerase activation or a telomerase-independent pathway called alternative lengthening of telomeres (ALT) (8).”
BackgroundAlhendi, A. S. N., & Royle, N. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-77606-w · Cited by 7
Vulliamy, T. J. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0091-6 · Cited by 8
Pendina, A. A., Krapivin, M. I., Sagurova, Y. M., Дмитриевна, М. И., Komarova, E. M., Tikhonov, A. V., Golubeva, A. V., Gzgzyan, A. M., Kogan, I. Y., & Efimova, O. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310427 · Cited by 7
Screening for telomeric recombination in wild-typeKluyveromyces lactis
Natarajan, S., Nickles, K., & McEachern, M. J. (2006) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2005.00042.x · Cited by 7
Telomere maintenance in soft tissue sarcomas
Eastley, N. C., Ottolini, B., Garrido, C., Shaw, J., McCulloch, T. A., Ashford, R. U., & Royle, N. J. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2016-204151 · Cited by 8
Sharaf, R., Montesion, M., Hopkins, J. F., Song, J., Frampton, G. M., & Albacker, L. A. (2022) · Genome Medicine · doi:10.1186/s13073-022-01029-7 · Cited by 9
“ALT, on the other hand, relies on homologous recombination, where portions of the telomeric region are copied over from one chromosome to another [10, 11].”
BackgroundTelomerase activity of Merkel cell carcinomas and Merkel cell carcinoma-derived cell cultures
Stöppler, H., Stoppler, M. C., Kisiela, M., Holzbach, A., Moll, I., Houdek, P., & Moll, R. (2001) · Archives of Dermatological Research · doi:10.1007/s004030100241 · Cited by 7
Shigeeda, N., Uchida, M., Barrett, J. C., & Tsutsui, T. (2003) · Experimental Gerontology · doi:10.1016/s0531-5565(03)00072-x · Cited by 8
Immunohistochemical TRF1 expression in human primary intracranial tumors.
Aragona, M., DIVITIIS, O. D., Torre, D. L., Panetta, S., D’Avella, D., Pontoriero, A., Morelli, M., Torre, I. L., & Tomasello, F. F. (2001) · PubMed · Cited by 7
Slowing Down Cellular Aging In Vitro
Trougakos, I. P., Chondrogianni, N., Pimenidou, A., Katsiki, M., Tzavelas, C., & Gonos, E. S. (2003) · Springer eBooks · doi:10.1007/978-94-017-0283-6_5 · Cited by 8
Manipulating mouse telomeres: models of tumorigenesis and aging
Xin, Z., & Broccoli, D. (2004) · Cytogenetic and Genome Research · doi:10.1159/000078221 · Cited by 9
“In the tumors that develop in telomerase-deficient mice, telomere maintenance occurs by the telomerase-independent ALT mechanism (Chang et al., 2003a).”
BackgroundInfluentialDissecting telomere maintenance mechanisms in pediatric glioblastomaPreprint
Deeg, K. I., Chung, I., Poos, A. M., Braun, D. M., Korshunov, A., Oswald, M., Kepper, N., Bender, S., Castel, D., Lichter, P., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/129106 · Cited by 9
“(iii) In line with previous reports that associated TP53 mutations with ALT, 12 of the 13 C-circle-positive tumors also harbored TP53 mutations [61-63].”
Sharaf, R., Jin, D. X., Grady, J. P., Napier, C. E., Ebot, E. M., Frampton, G. M., Albacker, L. A., Thomas, D. M., & Montesion, M. (2023) · npj Genomic Medicine · doi:10.1038/s41525-023-00369-6 · Cited by 9
“Herewesought to investigate the genomic determinants of high telomeric content beyond the canonical ATRX / DAXX alterations within our sarcoma dataset.”
BackgroundInfluentialCanonical and Non-Canonical Roles of Human DNA Polymerase η
Bedaiwi, S., Usmani, A., & Carty, M. P. (2024) · Genes · doi:10.3390/genes15101271 · Cited by 8
“The maintenance of telomere length at the ends of chromosomes, either by re-expression of telomerase [182], or by using the alternate lengthening of telomeres (ALT) pathway [183], is crucial for the survival of cancer cells.”
BackgroundQuintanilla, I., Azeroglu, B., Sagar, M. A. K., Stracker, T. H., Denchi, E. L., & Pegoraro, G. (2025) · Methods · doi:10.1016/j.ymeth.2025.05.001 · Cited by 7
Baliou, S., Pelagiadis, I., Apetroaei, M.-M., Vakonaki, E., Arsene, A. L., Hatzidaki, E., Tzatzarakis, M. N., Ιωάννου, Π., Tsatsakis, A. M., & Stiakaki, E. (2025) · Cancers · doi:10.3390/cancers17121936 · Cited by 7
“While a subgroup of cancer cells extend telomeres by telomerase-independent mechanisms known as alternative lengthening of telomeres (ALT) [26], telomerase has been understood to sustain telomere length in the overwhelming majority of cancer cells (80% to 90”
Genistein suppresses the proliferation of telomerase‐negative cells
Lin, C., Hsieh, M., & Teng, S. (2016) · Food Science & Nutrition · doi:10.1002/fsn3.382 · Cited by 6
“An indication of ALT telomere is the pattern of heterogeneous sizes (Bryan et al. 1997, 1995).”
BackgroundDirect Quantitative Monitoring of Homology-Directed DNA Repair of Damaged Telomeres
Verma, P., Dilley, R. L., Gyparaki, M. T., & Greenberg, R. A. (2018) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2017.11.010 · Cited by 6
Epigenetic Alterations: The Relation Between Occupational Exposure and Biological Effects in Humans
Kahl, V. F. S., Cappetta, M., & da Silva, J. (2019) · RNA technologies · doi:10.1007/978-3-030-14792-1_11 · Cited by 6
An overview of the molecular pathology of head and neck cancer, and its clinical implications
Hunter, K. D., Parkinson, E. K., & Thakker, N. (2011) · Periodontology 2000 · doi:10.1111/j.1600-0757.2011.00387.x · Cited by 8
Telomere length and Telomerase catalytic subunit expression in non-astrocytic gliomas
Chong, E. Y. Y., Pang, J. C. S., Ko, C., Poon, W. S., & Ng, H. (2000) · Pathology - Research and Practice · doi:10.1016/s0344-0338(00)80121-1 · Cited by 7
Exploring cellular senescence as a tumor suppressor mechanism
Carnero, A., Blanco‐Aparicio, C., Blanco, F., Castro, M. E., Guijarro, M. V., Fominaya, J. M., Link, W., Martínez, J. F., Moneo, V., Renner, O., et al. (2003) · Revista de Oncología · doi:10.1007/bf02711481 · Cited by 9
Krejčí, K., Stentof, J., & Koch, J. (1999) · Neoplasia · doi:10.1038/sj.neo.7900065 · Cited by 6
Clinical applications of telomerase in cancer treatment
Faraoni, I., Bonmassar, E., & Graziani, G. (2000) · Drug Resistance Updates · doi:10.1054/drup.2000.0139 · Cited by 6
Correction: Telomere Reprogramming and Maintenance in Porcine iPS Cells
Ji, G., Ruan, W., Liu, K., Wang, F., Sakellariou, D., Chen, J., Yang, Y., Okuka, M., Han, J., Liu, Z., et al. (2013) · PLoS ONE · doi:10.1371/annotation/f5e4554b-18cc-46ef-ac39-73ac4d6750ae · Cited by 6
Peng, B., Zhang, M., Sun, R. K. P., Lin, Y.-C., Chong, S. Y., Lai, H., Stein, D., & Raveche, E. S. (1998) · Leukemia Research · doi:10.1016/s0145-2126(98)00021-6 · Cited by 6
Telomeres and Cell Division Potential
Perrem, K., & Reddel, R. R. (1999) · Progress in molecular and subcellular biology · doi:10.1007/978-3-662-06227-2_8 · Cited by 6
Self-citationPrescott, J. C., & Blackburn, E. H. (2002) · Wiley eBooks · doi:10.1002/0471203076.emm1023 · Cited by 6
Son, J. H., Lawlor, M. A., Virani, M., Cao, W., Levine, M. T., & Ellison, C. E. (2026) · Genome Research · doi:10.1101/gr.281112.125 · Cited by 6
“…with a total of 13 Drosophila species (and two outgroup species) having lost telomeric TEs entirely and thus presumably relying on an alternative, recombination-based mechanism of chromosome elongation (i.e., alternative lengthening of telomeres [ALT]) (Bryan et al. 1997; Biessmann et al. 2000).”
Orphan nuclear receptors recruit TRIM28 to promote telomeric H3K9me3 for the ALT pathway
Tsai, C.-T., Gaela, V. M., Hsia, H.-Y., Huang, Y.-C., Shen, Y., & Chen, L. (2026) · The EMBO Journal · doi:10.1038/s44318-026-00760-w · Cited by 6
“ALT enacts homologous recombination (HR), reminiscent of break-induced replication, to lengthen telomeres and enable inde fi nite proliferation (Bryan et al, 1997; Dilley et al, 2016; Zhang et al, 2019).”
5-aza-2′-deoxycytidine induces telomere dysfunction in breast cancer cells
Al-dulaimi, S., Matta, S., Slijepčević, P., & Roberts, T. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117173 · Cited by 5
“Telomerase, the enzyme responsible for synthesising telomeric repeats, is expressed at very low levels in normal human somatic cells [3].”
BackgroundTargeting Telomerase in Hematologic Malignancy
Maritz, M. F., Napier, C. E., Wen, V. W., & MacKenzie, K. L. (2010) · Future Oncology · doi:10.2217/fon.10.42 · Cited by 5
“Another issue to be addressed in relation to antitelomerase therapeutics is the potential for cells derived from diverse tissue types to utilize the alternative lengthening of telomeres (ALT) mechanism for telomere elongation as a means of proliferating in the absence of telomerase [235,236].”
BackgroundYong, J., Yeo, X., Khan, M. M., Lee, M. B. H., & Hande, M. P. (2012) · Genome Integrity · doi:10.1186/2041-9414-3-5 · Cited by 6
“Some cancer cells also use the lesser-known telomere maintenance pathway-the Alternative Lengthening of Telomeres pathway, ALT [3,4].”
BackgroundZinc protoporphyrin binding to telomerase complexes and inhibition of telomerase activity*
Zhu, Z., Tran, H. T. T., Mathahs, M. M., Fink, B. D., Albert, J. A., Moninger, T. O., Meier, J. L., Li, M., & Schmidt, W. N. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.882 · Cited by 6
“This activity is so crucial to malignancy that even in the 15% of neoplastic cells that do not express telomerase, telomeric ends are maintained by an alternative recombination process (3).”
BackgroundEnhancing Anticancer Potency of a 13-Substituted Berberine Derivative with Cationic Liposomes
Apiratikul, N., Sriklung, K., Dolsophon, K., Thamvapee, P., Watanapokasin, R. Y., Yingyongnarongkul, B., Niyomtham, N., Bremner, J. B., Watanavetch, P., & Samosorn, S. (2022) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c21-01049 · Cited by 5
Pierpoint, M., Floyd, W., Wisdom, A. J., Luo, L., Ma, Y., Dickson, B. C., Waitkus, M. S., & Kirsch, D. G. (2025) · iScience · doi:10.1016/j.isci.2025.112357 · Cited by 6
Effects of Verapamil on Bone Cancer Cells in vitro
Dziak, R. (2016) · Cell Biology & Cell Metabolism · doi:10.24966/cbcm-1943/100013 · Cited by 4
Alternative Lengthening of Telomeres in the Budding Yeast Naumovozyma castellii
Cohn, M., Andersson, A. K., Mateo, R. Q., & Möller, M. C. (2019) · G3 Genes Genomes Genetics · doi:10.1534/g3.119.400428 · Cited by 5
Li, Y., Gu, J., Ding, Y., Gao, H., Li, Y., Sun, Y., He, M. T., Zhang, W., Yin, J., Bai, C., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201902651rr · Cited by 5
Telomerase in human tumors: molecular diagnosis andclinical significance
Dahse, R., & Mey, J. (2001) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.1.2.201 · Cited by 5
Hyper-Phosphorylated Retinoblastoma Protein Suppresses Telomere Elongation
Takemura, M., Sugimura, K., Okumura, K., Limsirichaikul, S., Suzuki, M., Yamada, Y., & Yoshida, S. (2008) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.70715 · Cited by 5
Absence of Telomerase Activity in Malignant Bone Tumors and Soft‐TissueSarcomas
Lauer, N. K., Maier, S. M., Oberringer, M., Schulte, M., Mutschler, W., Hanselmann, R. G., Schartl, M., Scherer, S. J., & Wirbel, R. (2002) · Sarcoma · doi:10.1080/13577140220127549 · Cited by 9
Nakamura, A., Suda, T., Honma, T., Takahashi, T., Igarashi, M., Waguri, N., Kawai, H., Mita, Y., & Aoyagi, Y. (2004) · Digestive Diseases and Sciences · doi:10.1023/b:ddas.0000042256.89282.c4 · Cited by 5
“Since immortal cells that do not express hTERT must maintain the telomere length in the absence of telomerase, it is possible that hTR plays a key role not only in telomerase activity, but also in alternative mechanisms of telomere maintenance termed alternative lengthening of telomeres (47, 48).”
BackgroundBondarev, I. E., & Khavinson, V. K. (2016) · Advances in Gerontology · doi:10.1134/s2079057016040020 · Cited by 5
Bocchetta, M., & Carbone, M. (2006) · Springer eBooks · doi:10.1007/0-387-28274-2_3 · Cited by 5
Targeted Inhibition of Telomerase in Human Cancer: Will It Be a Double-Edged Sword?
Sasgary, S., Wieser, M., & Cerni, C. (2001) · Oncology Research and Treatment · doi:10.1159/000050277 · Cited by 7
Repeat Expansion–Detection Analysis of Telomeric Uninterrupted (TTAGGG) Arrays
Sirugo, G., & Kídd, K. K. (1998) · The American Journal of Human Genetics · doi:10.1086/301961 · Cited by 5
Direct visualization of telomeric DNA loops in cells by AFM
Chen, A., Cao, E., Sun, X., Qin, J., Dage, L., Wang, C., & Bai, C. (2001) · Surface and Interface Analysis · doi:10.1002/sia.1000 · Cited by 5
The human Werner Syndrome as a model system for aging
Cheng, W., Opresko, P. L., von Kobbe, C., Harrigan, J. A., & Bohr, A. V. A. (2003) · Topics in current genetics · doi:10.1007/978-3-540-37005-5_9 · Cited by 5
Gu, W. L., Li, H., Sun, L., Shen, Z., Wang, Y., Hu, X., Wu, Y., Liu, W., Wan, C. C., Cai, Y., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123321 · Cited by 5
Aida, S., Aida, J., Hasegawa, K., Kumasaka, T., Shimazaki, H., Tamai, S., & Takubo, K. (2015) · Respiration · doi:10.1159/000437357 · Cited by 4
MacKinnon, R. N., Duivenvoorden, H. M., Campbell, L. J., & Wall, M. (2016) · Cytogenetic and Genome Research · doi:10.1159/000456677 · Cited by 5
“If apoptosis is suppressed and a telomere lengthening mechanism is activated, cells can overcome this ‘crisis’ to become immortal [Kim et al., 1994; Blasco et al., 1997; Bryan et al., 1997; Artandi et al., 2000].”
BackgroundNPCs and APBs: two HUBs of non-canonical homology-based recombination at telomeres?
Aguilera, P., Dubarry, M., Géli, V., & Simon, M. (2023) · Cell Cycle · doi:10.1080/15384101.2023.2206350 · Cited by 4
“Most human cancers upregulate telomerase [5], but about 10–15% of them rely on alternative lengthening of telomeres (ALT) based on homologydirected recombination (HDR) [6].”
BackgroundInfluentialChen, B., Weng, Y., Li, M., Bian, Z., Tao, Y., Zhou, W., Lu, H., He, S., Liao, R., Huang, J., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216734 · Cited by 5
Liu, X., Wang, J., Su, D., Wang, Q., Li, M., Zhengyao, Z., Han, Q., Li, X., Fameng, Z., Fan, M., et al. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-2294 · Cited by 5
Andreikos, D., Spandidos, D. A., & Georgakopoulou, V. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5729 · Cited by 5
“A minority activates telomerase‑independent mechanisms, denoted as alternative lengthening of telo‑ meres (ALT) (83,84).”
The Mechanisms of Telomere and Telomerase Regulation in Hematologic Malignancies
Kawauchi, K., Akiyama, M., & Yamada, O. (2013) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608057986113010005 · Cited by 5
“Rare cells can escape from this crisis and become immortalized by activating telomerase or, in some cases, by utilizing an alternative telomere lengthening mechanism [10].”
BackgroundTelomere Maintenance and Genome Stability
Hernandez-Sanchez, W. M., Xu, M., & Taylor, D. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803309-8.00021-5 · Cited by 5
Telomeres and Telomerase in Neuroblastoma
Hajj, J. E., Garsuault, D., Bouyer, C., Nguyen, É., Hilal, G., & Ségal-Bendirdjian, E. (2017) · InTech eBooks · doi:10.5772/intechopen.69567 · Cited by 5
“Two mechanisms of telomere maintenance have been identified in humans: the telomerasemediated maintenance observed in 90% of cancers and, in the remaining 10%, the alternative lengthening of telomeres (ALT), which depends on homologous recombination [29, 30].”
BackgroundCellular senescence and cancer
(1999) · doi:10.1002/(sici)1096-9896(199901)187:1
Metadata
- Authors
- Bryan, T. M., Englezou, A., Dalla-Pozza, L., Dunham, M. A., & Reddel, R. R.
- Affiliations
- Children's Medical Research Institute (AU)
- Corresponding author
- Reddel, Roger R.
- Venue
- Nature Medicine
- Published
- 1997-11
- Volume
- 3
- Issue
- 11
- Pages
- 1271-1274
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2013073993
- Cited by
- 1,292
- References
- 39
- Citations by year
- 2026: 19 · 2025: 41 · 2024: 37 · 2023: 48 · 2022: 31 · 2021: 34 · 2020: 44 · 2019: 52 · 2018: 27 · 2017: 54 · 2016: 35 · 2015: 52 · 2014: 33 · 2013: 52 · 2012: 39
- FWCI
- 27.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Keywords
- alternative lengthening of telomeres, telomere maintenance, telomerase, tumor-derived cell lines, cell immortalization, telomerase inhibitors, cancer therapy, telomere loss
- MeSH terms
- Adult, DNA Nucleotidyltransferases, Humans, Neoplasms, Tumor Cells, Cultured, Deoxyribonucleases, Type II Site-Specific, Telomere, Telomerase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.